BiomX Inc.
Company Information
Industry Biological Products, (No Diagnostic Substances)
SIC Code 2836
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation DE
Business Address 850 NEW BURTON ROAD, DOVER, DE, 19904
Mailing Address 850 NEW BURTON ROAD, DOVER, DE, 19904
Phone 972 545610935
Fiscal Year End 1231
EIN 823364020
Financial Overview
FY2025
$4.36M
Cash & Equivalents
$22.19
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | March 27, 2026 | View on SEC |
| DEF 14A Definitive proxy statement | March 25, 2026 | View on SEC |
| 8-K Current report of material events | March 19, 2026 | View on SEC |
| 4 Insider stock transaction report | March 18, 2026 | View on SEC |
| 4 Insider stock transaction report | March 13, 2026 | View on SEC |
| 8-K Current report of material events | March 11, 2026 | View on SEC |
| 8-K Current report of material events | March 6, 2026 | View on SEC |
| 3 Initial insider ownership report | March 3, 2026 | View on SEC |
| 8-K Current report of material events | March 2, 2026 | View on SEC |
| 8-K Current report of material events | February 25, 2026 | View on SEC |
Annual Reports
10-K February 19, 2026
- Pioneering phage technology with two clinical candidates: BX004 in Phase 1b/2a for CF and BX005 in preclinical for IBD.
- Secured critical $3.0 million financing from Pyu Pyu Capital in late 2025, essential for continued operations.
Material Events
8-K Financial Distress March 27, 2026
High Impact
- Developing innovative phage therapies for cystic fibrosis and chronic sinus issues
- Active clinical research pipeline including the BX004 program
8-K Leadership Change March 6, 2026
High Impact
- BiomX undergoes a major leadership overhaul, with CEO Jonathan Solomon and Chairman Dr. Russell Greig resigning.
- Michael Oster, an M&A and operational strategy expert, appointed as new CEO, signaling a potential strategic pivot.
8-K Strategy Change February 10, 2026
High Impact
- BiomX Inc. is streamlining its focus on lead clinical programs: BX004 (Phase 2b) and BX003 (preclinical/early clinical).
- Deconsolidation of the struggling Israeli subsidiary is projected to significantly reduce cash burn and extend the cash runway.
8-K Bankruptcy December 11, 2025
High Impact
- BiomX Inc.'s main Israeli subsidiary, BiomX Ltd., is initiating insolvency proceedings (a form of bankruptcy).
- This decision follows BiomX Inc.'s discontinuation of a major Phase 2b drug study due to financial constraints.
8-K Strategy Change December 8, 2025
High Impact
- BiomX Inc. discontinued the development of its main drug candidate, BX004, aimed at treating cystic fibrosis.
- The company is implementing significant cost-cutting measures, including a substantial reduction in its workforce.
Insider Trading
STRONG SELL 1 insiders
4 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2836)
SANGAMO THERAPEUTICS, INC
SGMO Biological Products, (No Diagnostic Substances)
Zivo Bioscience, Inc.
ZIVO Biological Products, (No Diagnostic Substances)
Quince Therapeutics, Inc.
QNCX Biological Products, (No Diagnostic Substances)
EXOZYMES INC.
EXOZ Biological Products, (No Diagnostic Substances)
Aura Biosciences, Inc.
AURA Biological Products, (No Diagnostic Substances)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.